Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 167, Issue 4, 2014, Pages 487-499

  Satake, Noriko ^a,b   Duong, Connie ^a,b   Chen, Cathy ^a,b   Barisone, Gustavo A ^b   Diaz, Elva ^b   Tuscano, Joseph ^a   Rocke, David M ^b   Nolta, Jan ^b   Nitin, Nitin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AntiCD22 antibody; MXD3 siRNA; Precursor B cell acute lymphoblastic leukaemia; RNA inhibition; Superparamagnetic iron oxide nanoparticle

Indexed keywords

ANTILEUKEMIC AGENT; DOXORUBICIN; MAX DIMERIZATION PROTEIN 3 CD22 ANTIBODY COMPLEX; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; VINCRISTINE; CANCER ANTIBODY; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; MAGNETITE NANOPARTICLE; MONOCLONAL ANTIBODY; MXD3 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B-CELL LEUKEMIA CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; FEMALE; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; FEMALE; HUMANS; MAGNETITE NANOPARTICLES; MALE; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASM PROTEINS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIALIC ACID BINDING IG-LIKE LECTIN 2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916196785     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13066     Document Type: Article

References (33)

1. August, K.J., Narendran, A. & Neville, K.A. (2013) Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. Drugs, 73, 439-461.
2. Barth, M., Raetz, E. & Cairo, M.S. (2012) The future role of monoclonal antibody therapy in childhood acute leukaemias. British Journal of Haematology, 159, 3-17.
3. Boue, D.R. & LeBien, T.W. (1988) Expression and structure of CD22 in acute leukemia. Blood, 71, 1480-1486.
4. Brown, P. (2013) Treatment of infant leukemias: challenge and promise. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2013, 596-600.
5. Daver, N. & O'Brien, S. (2013) Novel therapeutic strategies in adult acute lymphoblastic leukemia-a focus on emerging monoclonal antibodies. Current Hematologic Malignancy Reports, 8, 123-131.
6. Doane, T.L., Chuang, C.H., Hill, R.J. & Burda, C. (2012) Nanoparticle zeta -potentials. Accounts of Chemical Research, 45, 317-326.
7. Duan, J., Dong, J., Zhang, T., Su, Z., Ding, J., Zhang, Y. & Mao, X. (2014) Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis. Nanomedicine, 9, 789-801.
8. Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., Dimitrov, D.S., Morgan, R.A., FitzGerald, D.J., Barrett, D.M., Wayne, A.S., Mackall, C.L. & Orentas, R.J. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 121, 1165-1174.
9. Hochhaus, A. & Kantarjian, H. (2013) The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Journal of Cancer Research and Clinical Oncology, 139, 1971-1984.
10. Hoelzer, D. (2013) Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Current Opinion in Oncology, 25, 701-706.
11. Hothorn, T. & Zeileis, A. (2008) Generalized maximally selected statistics. Biometrics, 64, 1263-1269.
12. Hothorn, T., Bretz, F. & Westfall, P. (2008) Simultaneous inference in general parametric models. Biometrical Journal, 50, 346-363.
13. Kato, J., Satake, N., O'Donnell, R.T., Abuhay, M., Lewis, C. & Tuscano, J.M. (2013) Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leukemia Research, 37, 83-88.
14. Kreitman, R.J. & Pastan, I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clinical Cancer Research, 17, 6398-6405.
15. Krishnan, V. & Rajasekaran, A.K. (2014) Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy. Clinical Pharmacology and Therapeutics, 95, 168-178.
16. Kumar, R., Kaur, M. & Silakari, O. (2013) Physiological modulation approaches to improve cancer chemotherapy: a review. Anti-Cancer Agents in Medicinal Chemistry, 14, 713-749.
17. Li, J., Gupta, S. & Li, C. (2013) Research perspectives: gold nanoparticles in cancer theranostics. Quantitative Imaging in Medicine and Surgery, 3, 284-291.
18. Litzow, M.R. (2013) Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. American Society of Clinical Oncology Educational Book/ASCO. American Society of Clinical Oncology Meeting, 294-299.
19. van der Meel, R., Vehmeijer, L.J., Kok, R.J., Storm, G. & van Gaal, E.V. (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Advanced Drug Delivery Reviews, 65, 1284-1298.
20. Mullighan, C.G. (2012) Molecular genetics of B-precursor acute lymphoblastic leukemia. The Journal of Clinical Investigation, 122, 3407-3415.
21. Mussai, F., Campana, D., Bhojwani, D., Stetler-Stevenson, M., Steinberg, S.M., Wayne, A.S. & Pastan, I. (2010) Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 150, 352-358.
22. Pui, C.H., Robison, L.L. & Look, A.T. (2008) Acute lymphoblastic leukaemia. Lancet, 371, 1030-1043.
23. Ramsay, A.D. & Rodriguez-Justo, M. (2013) Chronic lymphocytic leukaemia-the role of the microenvironment pathogenesis and therapy. British Journal of Haematology, 162, 15-24.
24. de Rosales, R.T. (2014) Potential clinical applications of bimodal PET-MRI or SPECT-MRI agents. Journal of Labelled Compounds & Radiopharmaceuticals, 57, 298-303.
25. Sanz, M.A., Iacoboni, G. & Montesinos, P. (2013) Acute promyelocytic leukemia: do we have a new front-line standard of treatment? Current Oncology Reports, 15, 445-449.
26. Schindler, J., Gajavelli, S., Ravandi, F., Shen, Y., Parekh, S., Braunchweig, I., Barta, S., Ghetie, V., Vitetta, E. & Verma, A. (2011) A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 154, 471-476.
27. Shah, V., Taratula, O., Garbuzenko, O.B., Patil, M.L., Savla, R., Zhang, M. & Minko, T. (2013) Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Current Drug Discovery Technologies, 10, 8-15.
28. Sullivan-Chang, L., O'Donnell, R.T. & Tuscano, J.M. (2013) Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs, 27, 293-304.
29. Taratula, O., Garbuzenko, O., Savla, R., Wang, Y.A., He, H. & Minko, T. (2011) Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Current Drug Delivery, 8, 59-69.
30. Thomas, D.A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J.L., Bueso-Ramos, C., Andreeff, M., Pierce, S., Garris, R., Keating, M.J., Cortes, J. & Kantarjian, H.M. (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology, 28, 3880-3889.
31. Tong, L., Zhao, M., Zhu, S. & Chen, J. (2011) Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer. Frontiers of Medicine, 5, 379-387.
32. Wiemels, J. (2012) Perspectives on the causes of childhood leukemia. Chemico-Biological Interactions, 196, 59-67.
33. Zerra, P., Cochran, T.R., Franco, V.I. & Lipshultz, S.E. (2013) An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert opinion on Pharmacotherapy, 14, 1497-1513.